 Hoth Therapeutics Inc NASDAQ: HOTH has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis. HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival, and differentiation of bone marrow-derived hematopoietic stem cells. 